Delcath Systems, Inc. (NASDAQ:DCTH) Short Interest Update

Delcath Systems, Inc. (NASDAQ:DCTH) was the recipient of a large decrease in short interest in February. As of February 28th, there was short interest totalling 700,600 shares, a decrease of 20.5% from the February 13th total of 881,500 shares. Based on an average trading volume of 401,400 shares, the short-interest ratio is currently 1.7 days. Currently, 2.7% of the company’s shares are short sold.

Delcath Systems Price Performance

Shares of DCTH stock opened at $12.58 on Monday. Delcath Systems has a 12 month low of $3.93 and a 12 month high of $16.97. The company’s fifty day moving average price is $14.40 and its two-hundred day moving average price is $11.82. The firm has a market capitalization of $420.21 million, a P/E ratio of -9.32 and a beta of 0.82.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. The business had revenue of $15.10 million during the quarter, compared to analyst estimates of $14.96 million. During the same period last year, the firm posted ($0.48) earnings per share. On average, sell-side analysts anticipate that Delcath Systems will post -0.79 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Craig Hallum upped their price target on Delcath Systems from $18.00 to $21.00 and gave the stock a “buy” rating in a report on Friday, January 17th. HC Wainwright increased their price target on shares of Delcath Systems from $22.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, March 7th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Delcath Systems presently has a consensus rating of “Moderate Buy” and an average price target of $22.75.

Hedge Funds Weigh In On Delcath Systems

Several hedge funds have recently modified their holdings of DCTH. Jefferies Financial Group Inc. purchased a new position in shares of Delcath Systems in the fourth quarter worth approximately $251,000. Palisades Investment Partners LLC increased its stake in shares of Delcath Systems by 13.1% during the 4th quarter. Palisades Investment Partners LLC now owns 169,327 shares of the company’s stock worth $2,039,000 after purchasing an additional 19,671 shares during the last quarter. PharVision Advisers LLC bought a new position in Delcath Systems during the fourth quarter valued at about $129,000. Soleus Capital Management L.P. acquired a new stake in Delcath Systems in the 4th quarter worth approximately $9,644,000. Finally, Squarepoint Ops LLC lifted its stake in shares of Delcath Systems by 56.3% in the fourth quarter. Squarepoint Ops LLC now owns 79,537 shares of the company’s stock worth $958,000 after buying an additional 28,662 shares during the last quarter. 61.12% of the stock is currently owned by institutional investors and hedge funds.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.